Spun out of the University of Florida, 42Bioâs mission is to develop and implement regenerative medicine technologies to advance human and veterinary health. The objective of 42Bio is to apply magnetic and biomolecule technologies to address unmet needs in clinical and veterinary disease and injury. The firm's technologies in development include a magnetic separation system for purification of SARS-CoV-2 therapeutic antibodies, a unique biomolecule extraction from the placenta for regenerative medicine applications, and magnetic separation for the isolation of stem cells from cord tissue for research applications
